Advertisement

Related Videos

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement




Dec
10
Today In Oncology
Study Identifies Rectal Bleeding as Key Predictor of Early-Onset Colorectal Cancer
Abbreviated Azacitidine Regimen Improves Outcomes in Lower-Risk MDS
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Chemotherapy-Free Regimen Improves Outcomes in Newly Diagnosed Patients With Ph-Positive ALL
Experimental CAR T-Cell Therapy Shows High Efficacy and a Favorable Safety Profile in Multiple Myeloma
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo